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Carbonic anhydrase (CAIX)Human papillomaviruses (HPV) are the causative agents of cervical cancer and have been shown to increase
expression of pro-angiogenic factors from infected cells. Many angiogenic factors are regulated by hypoxia
inducible factor 1α (HIF-1α). We investigated whether HPV31 affects the levels of HIF-1α under normal and
hypoxic conditions. Our studies indicate that cells containing complete HPV31 genomes showed enhanced
levels of HIF-1α upon treatment with the hypoxia mimic DFO, which resulted from protein stabilization and
led to increased expression of some but not all HIF-1α target genes. Both HPV E6 and E7 were able
independently to enhance induction of HIF-1α upon DFO treatment. Enhancement of HIF-1α stability was
not restricted to high-risk HPV types, as HPV11, a low risk HPV type, mediated a similar effect. These ﬁndings
shed light on mechanisms by which HPV contributes to angiogenesis both in benign cervical lesions and in
cervical cancers.
© 2009 Elsevier Inc. All rights reserved.IntroductionHuman papillomaviruses (HPVs) are small, non-enveloped DNA
viruses that persistently infect the keratinocytes of stratiﬁed squa-
mous epithelia (zur Hausen, 1999). HPVs are linked to a variety of
malignancies including over 99% of cervical cancers (zur Hausen,
1996). HPVs infect the basal keratinocytes of stratiﬁed squamous
epithelia (Longworth and Laimins, 2004). As keratinocytes detach
from the basement membrane and begin the process of squamous
differentiation, HPV maintains the continued expression of cellular
DNA replication proteins for use in replicating its own genome, and
harnesses cellular regulatory mechanisms to control productive viral
replication and expression of its capsid genes (Longworth and
Laimins, 2004).
HPV gene products can induce many of the cellular changes
characteristic of the tumor phenotype (Hanahan andWeinberg, 2000;
Zitvogel et al., 2006), including independence from growth control
signals (Suprynowicz et al., 2000; Woodworth et al., 1992); bypass of
growth inhibitory signals, especially cellular differentiation (Hudson
et al., 1990; Ruesch and Laimins, 1998); resistance to apoptosis
(Webster et al., 2000; Zhang et al., 2002); immune evasion (O'Brien
and Saveria Campo, 2002); and angiogenesis (Toussaint-Smith et al.,imins).
ll rights reserved.2004). The two primary viral oncogenes, E6 and E7, are the only HPV
gene products that are consistently retained and expressed in cervical
cancers, indicating these two factors are responsible for malignant
progression induced by HPV infection (Munger et al., 2004). E6 and E7
function in large part by binding and promoting the degradation of
cellular tumor suppressors p53 and pRb, respectively (Munger et al.,
2004). Degradation of pRb by E7 results in the activation of E2F
transcription factors that drive expression of cellular genes respon-
sible for the S phase of the cell cycle. E7-driven cell cycle progression
can result in or potentiate cell death by apoptosis through upregula-
tion of p53. Degradation of p53 mediated by E6 blocks apoptosis to
allow continued proliferation. In addition to these well known
activities, both oncogenes have a range of other targets (Munger et
al., 2004), and the extent to which these additional interactions
contribute to HPV associated carcinogenesis is not fully understood.
One important characteristic of tumor development is the
promotion of angiogenesis, or the formation of new blood vessels,
which allows for access to nutrients and oxygen for growth (Hanahan
and Folkman, 1996). Angiogenesis is induced in response to hypoxia,
or reduced tissue oxygen levels (Brat et al., 2003). Under hypoxic
conditions, cells secrete a variety of cytokines and growth factors that
induce proliferation, migration, and blood vessel formation by
endothelial cells (Brat et al., 2003). The cellular response to hypoxia
is primarily regulated through the activity of the transcription factor
hypoxia inducible factor-1 (HIF-1) (Bardos and Ashcroft, 2005; Brat et
al., 2003). HIF-1 has two subunits, of which HIF-1α is regulated by
Fig. 1. Over-induction of HIF-1α in HPV31 containing cells. (a) CIN 612 cells were
treated with the indicated compound for 12 h or 1.5% oxygen for 48 h. Total cell extracts
were examined for HIF-1α levels byWestern blotting. (b) HFK-1 and HK31-1 cells were
treated with 100 μMDFO for the indicated times, and lysates were analyzed byWestern
blotting for HIF-1α expression.
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subunit is hydroxylated, targeting it for rapid degradation through the
von Hippel–Lindau (VHL)/proteasome pathway. In hypoxia, reduced
oxygen levels block VHL-mediated degradation, resulting in the
accumulation of HIF-1α protein, which translocates to the nucleus
and activates expression of HIF-1 target genes (Bardos and Ashcroft,
2005). In addition to this hypoxia-dependent stabilization system, a
range of other post-translational modiﬁcations and signaling path-
ways, such as the PI3K/mTOR pathway, also affect HIF-1α synthesis,
stability, and activity (Abraham, 2004; Bardos and Ashcroft, 2005;
Brat et al., 2003).
In many cancers, angiogenesis occurs only late in tumor progres-
sion, but increased vascular density and production of angiogenic
factors is a very early event in the development of HPV-induced pre-
malignant lesions and cervical cancers (Smith-McCune et al., 1997;
Smith-McCune andWeidner, 1994). Furthermore, several studies have
reported that HPV gene products can inﬂuence the production of
angiogenic factors (Chen et al., 2007; Clere et al., 2007; Tang et al.,
2007; Toussaint-Smith et al., 2004). HIF-1α often continues to be
expressed in advanced cervical carcinomas, as well, and is a marker of
poor response to therapy (Bachtiary et al., 2003; Ishikawa et al., 2004).
Despite these observations, the molecular mechanisms by which HPV
proteins induce an angiogenic phenotype remain largely unexplored.
Since HIF-1α is a central mediator of the angiogenic response in
hypoxia, we investigated whether HPV affects the levels of HIF-1α
expressed under normoxic or hypoxic conditions. Our results indicate
that the levels of HIF-1α protein are increased in hypoxia when HPV
oncogenes are present, and this was true for both high and low risk
virus types. Furthermore, this increased HIF-1α induction resulted in
increases in some but not all downstream effectors of the hypoxic
response, suggesting that HPV speciﬁcally manipulates aspects of the
cellular hypoxic response.
Results
HPV31 and 16 proteins enhance activation of HIF-1α under
hypoxic conditions
To determine whether expression of HPV genes had any inﬂuence
upon HIF-1α activation or levels in normoxia and hypoxia, we ﬁrst
examined whether HIF-1α levels were induced in hypoxia using an
HPV31-containing cell line (CIN 612) derived from a pre-malignant
cervical biopsy (Rader et al., 1990). To facilitate analysis we used the
hypoxic mimic drug, deferoxamine mesylate (DFO) which has been
previously reported to increase the levels of HIF-1α in a manner
similar to that seen following growth in 1.5% oxygen (An et al., 1998).
As a control we examined the levels of induction with cobalt chloride,
a second hypoxic mimic drug. As seen in Fig. 1a, treatment of CIN 612
cells with DFO or cobalt chloride induced similar levels of HIF-1α
protein as seen following growth for 48 h in 1.5% oxygen. For ease of
use we used DFO treatment in subsequent experiments.
We next investigated whether HPV proteins enhanced the levels of
HIF-1α in normoxia or hypoxia. Additional HPV31 positive cell lines
were generated by transfection of HPV31 DNA into human foreskin
keratinocytes (HFK) followed by drug selection and expansion
(Wilson and Laimins, 2005). This allowed us to make direct
comparisons between normal keratinocytes and keratinocytes con-
taining HPV genomes in the same genetic background. Southern
blotting conﬁrmed that these cell lines maintained HPV episomes at
similar copy number (not shown). To ensure that any differences we
observed were not a result of genetic factors, we performed all
experiments multiple times using different HFK donors and compared
HPV31-positive cells with HFKs from the same donor. Cell lines were
designated HK31 cells, and distinguished from each other according to
the HFK donor (i.e. the HK31-1 line was derived from HFK-1, etc.)
HFKs and HK31 cells were treated with DFO for various lengths of timeand compared the levels of HIF-1α byWestern blot analysis. As seen in
Fig. 1b, HIF-1αwas not detected above background in either HFK cells
or HK31 cells in the absence of DFO treatment. This indicates that the
presence of HPV genomes is not sufﬁcient by itself to induce HIF-1α
expression under conditions of normoxia. Failure to detect HIF-1α in
normoxia was also seen in cells containing only the HPV E6 and E7
genes, and in cervical cancer cell lines HeLa and C33A (not shown).
After incubation with DFO, HIF-1α levels were increased in both cell
typeswithin 3 h after the initiation of treatment. This indicates HIF-1α
levels can be increased in response to hypoxia in cells containing HPV.
However, HIF-1α levels were consistently increased to a higher degree
in HK31 cells as compared to HFK cells, indicating that HPV31 proteins
act to enhance induction of HIF-1α in hypoxia. Quantitative analysis of
eight experiments indicated that HIF-1α levels were approximately
2.5 fold higher on average in HPV31 positive cells as compared to HFK
with a range of 1.5 to 7 fold (data not shown). Similar enhancement of
HIF-1α levels was also seen in cell lines harboring episomal forms of
HPV16 (data not shown). Themultiple bands occasionally seen in HIF-
1α Western blots (see also Fig. 5) are of unknown signiﬁcance, but
have also been seen in other published reports (Schmid et al., 2004;
Tang et al., 2007) and may represent post-translational modiﬁcations
such as phosphorylation or ubiquitination.
The oncogenic herpesvirus, HHV8, increases the levels of HIF-1α in
infected cells by increasing transcription of the HIF1A gene (Carroll et
al., 2006), whereas regulation of HIF-1α usually occurs through post-
translational mechanisms in other systems (Bardos and Ashcroft,
2005). To determine if increased levels of HIF-1α seen in HK31 cells
was due to increased transcription of the HIF1A gene, Northern blot
analysis was performed on RNAs from DFO-treated HFKs and HK31
cells. No differences in HIF-1α mRNA levels were found (Fig. 2a),
indicating that the upregulation of HIF-1α is due to post-transcrip-
tional events. We next investigated whether the increase in HIF-1α
protein levels was due to changes in protein stability. HFKs or HK31
cells were treatedwith DFO for 6 h, with the addition of cycloheximide
for various lengths of time before harvesting (Fig. 2b). Levels of HIF-
1αwere determined by Western blotting, and the half lives of HIF-1α
in both cell typeswere calculated, taking into account the difference in
total expression levels between HFKs and HK31 cells. Our studies
found that the half life of HIF-1α was extended from approximately
39 min in HFKs to 59 min in HK31 cells (Fig. 2c). These data indicate
that enhanced induction of HIF-1α by HPV31 is due to increased
stability of the HIF-1α protein.
The PI3K/mTOR pathway has also been reported to result in
hypoxia-speciﬁc upregulation of HIF-1α protein synthesis, an effect
that can be inhibited by treatment with rapamycin (Abraham, 2004;
Fig. 3. Effect of rapamycin on HIF-1α protein levels. (a) HFKs or HK31-2 cells were
treated with the indicted drug for 6 h. Total cell lysates were analyzed for HIF-1α
expression by Western blotting. (b) Band densities from three independent experi-
ments were normalized ﬁrst to the level of GAPDH in each sample and then to the total
level of HIF-1α without treatment for each cell line. Bars represent±one standard
error of the mean.
Fig. 2.HIF-1α regulation by increased protein stability. (a) HFK-1 cells, HK31-1 cells, or HFKs transducedwith the indicated HPV16 oncogene(s) were treated with 100 μMDFO for the
indicated times. Total RNAwas isolated and subjected to Northern analysis using a probe speciﬁc for HIF-1α. (b) HFK cells or HK31 cells were treated with DFO for 6 h. Cycloheximide
(50 μg/ml ﬁnal) was added at the indicated times before cells were harvested. Lysates were analyzed by SDS-PAGE/Western blot for HIF-1α. (c) Band densities from three
independent experiments were normalized ﬁrst to the level of GAPDH in each sample and then to the total level of HIF-1α without cycloheximide treatment for each cell line. Bars
represent±one standard error of the mean.
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contributed to increased HIF-1α expression in HK31 cells, we treated
cells with both DFO and rapamycin, and then examined HIF-1α levels
by Western blot analysis. Rapamycin had a minimal effect on
induction of HIF-1α in either HK31 cells or HFKs, regardless of DFO
treatment (Fig. 3). We conclude that HPV proteins do not modulate
HIF-1α protein levels through the PI3K/mTOR pathway under our
culture conditions.
Activation of HIF-1α target genes by HPV31
HIF-1 regulates the transcription of dozens of genes associated
with angiogenesis, tumorigenesis, and glycolytic metabolism, many of
which contain hypoxia response elements (HRE) in their promoters
(Bardos and Ashcroft, 2005; Brat et al., 2003). To investigate whether
the ability of HIF-1 to act as a transactivator is altered in HK31 cells, we
ﬁrst used reporter plasmids containing several HREs located upstream
of luciferase under the control of the tk promoter (Alam et al., 2004).
This HIF-1 responsive reporter was transfected into HK31 cells or HFKs
that had been infected as an LXSN drug resistance-encoding retrovirus
as a control. After overnight incubation, cells were treated with DFO
for 8 h or left untreated. HIF-1 dependent luciferase activity in cell
lysates is shown in Fig. 4a as a ratio of luciferase activity in cells treated
with DFO versus untreated cells. While both HK31 cells and controls
showed an increased level of HRE-dependent luciferase activity
following treatment with DFO, HK31 cells showed a greater than
two-fold increase in activity as compared to controls, in line with the
enhanced HIF-1α levels we observed in HK31 cells.
We next investigated whether expression of endogenous HIF-1
targets would be similarly enhanced in HPV-containing cells. Vascular
endothelial growth factor (VEGF) is an important pro-angiogenic HIF-1 target gene and a central player in angiogenic signaling (Rankin and
Giaccia, 2008). The levels of VEGF transcripts were examined by
quantitative RT-PCR in normoxia and following treatment with DFO.
VEGF transcripts were induced to a higher level in HK31 cells than in
HFKs following treatment with DFO, consistent with higher levels of
Fig. 4. Regulation of HIF-1 targets by HPV31. (a) HK31-1 or HFK-1 cells transduced with
a LXSN retroviral vector were transfected with the HRE-TK-Luc reporter plasmid. The
next day, cells were treated or untreated with 100 μM DFO for 8 h and assayed for
luciferase activity. The data points represent a ratio of the activity with DFO treatment
to the activity without for three experiments and bars represent±one standard error of
the mean. (b) Total RNAs from HK31-1 or HFK-1 cells treated with DFO for the indicated
times were subjected to reverse transcription followed by real time PCR using primers
speciﬁc for VEGF. Bars represent±one standard error of the mean. Total RNAs from the
HFK-3 or HK31-3 cells were examined for expression of (c) CAIX or GLUT1 by Northern
analysis or (d) IL8 expression by ribonuclease protection assay.
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HPV would enhance the expression of all HIF-1 targets or only those
associatedwith angiogenesis. Among themany HIF-1 targets, carbonic
anhydrase IX (CAIX), which helps control cellular pH, and GLUT1, a
glucose transporter, are not associated directly with angiogenesis but
are upregulated during carcinogenesis (Lee et al., 2007). Northern blot
analysis indicated CAIX transcripts were increased to a greater degree
(mean of about 1.8 fold) in HK31 cells treatedwith DFO as compared to
similarly treated HFKs. In contrast, GLUT1 transcripts were expressed
at similar basal levels in untreated HFK and HK31 cells, and induced to
comparable levels following DFO treatment (Fig. 4c).
HIF-1 regulates some genes which could be detrimental to the
persistence of virally infected cells. One of these is interleukin-8 (IL8),
which, in addition to angiogenic activity also promotes inﬂammatory
responses (Brat et al., 2003). To test whether HPV31 induces IL8 in
hypoxic conditions, we performed ribonuclease protection assays on
RNA from cells treated or untreated with DFO. As shown in Fig. 4d, notonly were transcripts for IL8 not induced by DFO in HFK-derived cells,
expression of this gene was dramatically reduced by HPV31, in
contrast to the expression proﬁle of HIF-1α protein (Fig. 1), but in
agreement with the downregulation of IL8 by HPV oncogenes
observed by others in normoxia (Huang and McCance, 2002).
Together these experiments indicate that enhanced HIF-1α induction
by HPV results in activation of a subset of HIF-1 target genes, and that
HPV may alter the spectrum of genes activated by HIF-1α.
Both E6 and E7 can enhance induction of HIF-1α
HK31 cells maintain the entire HPV31 episomal genome, and so
any of the HPV31 gene products could potentially be involved in
regulating HIF-1α. We investigated whether the oncogenes E6 and E7
were sufﬁcient to enhance HIF-1α levels since these proteins are
selectively retained in cancers and previous reports indicate that they
are capable of regulating some angiogenic genes (Baker et al., 1987;
Tang et al., 2007; Toussaint-Smith et al., 2004). Furthermore, E6
promotes the degradation of p53 (Scheffner et al., 1990), which is
reported to negatively regulate HIF-1α stability in hypoxia (Ravi et al.,
2000). HFKs stably expressing HPV31 E6 or E7 were generated
following infection with LXSN-based retroviral vectors, selection for
G418 resistance, and expansion in culture (Thomas and Laimins,
1998). Following treatment with DFO, the levels of HIF-1α were
examined. As seen in Figs. 5a and b, HPV31 E6 and E7 were each
sufﬁcient on their own to cause enhanced induction of HIF-1α upon
DFO treatment. Similar effects were seen in cell lines expressing E6 or
E7 fromHPV16 (Fig. 5c). In none of these cell lines were the levels HIF-
1α transcripts altered (Fig. 2a). We conﬁrmed that p53 levels were
reduced in E6-expressing cells and enhanced in E7 expressing cells, in
line with previous observations (Eichten et al., 2002; Scheffner et al.,
1990) (data not shown). This indicates that the mechanism(s)
regulating enhanced stability of HIF-1α in HPV positive cells does
not depend exclusively on p53 protein levels.
Low risk HPV11 also enhances HIF-1α levels upon DFO treatment
Infection by low risk HPV types induces benign hyperproliferations
that rarely progress to cancers. Stabilization of HIF-1α as amechanism
of inducing angiogenesis during the development of cancers has been
well documented (Zhou et al., 2006), but benign HPV-induced lesions
likely also require the expression of angiogenic factors to ensure
adequate oxygen and nutrient supply for growth. We therefore sought
to determine whether cells containing the low risk type HPV11 would
also show enhanced induction of HIF-1α under hypoxic conditions.
For these studies, we transfected HFKs with cloned and recircularized
HPV11 genomes (Oh et al., 2004). Following drug selection and
expansion, we determined by Southern analysis that viral DNA was
maintained as episomes (not shown). We then treated HPV11 positive
cells with DFO and examined the levels of HIF-1α by Western blot
analysis. As shown in Fig. 6, HIF-1α expression in hypoxia was
enhanced in HFKs containing HPV11 episomes, similar to the effect
seen with HK31 cells, with a mean enhancement of about 2.5 fold.
Thus, the increased levels of HIF-1α proteins induced during hypoxia
appear to be a property of both high and low risk papillomaviruses.
Discussion
The development of cervical cancers requires angiogenesis, but
exhibits some unique differences from other solid tumors. Normal
stratiﬁed epithelia, including cervix, have characteristics of chroni-
cally hypoxic tissue, such as HIF-1α stabilization and VEGF expression,
which are further increased during progression to malignancy (Evans
et al., 2006; Lee et al., 2007; Mayer et al., 2004; Mazibrada et al., 2008;
Smith-McCune et al., 1997). Increased vascularity is observed in low
grade HPV infections of the cervix, while this is usually a late event in
Fig. 5. Enhanced induction of HIF-1α in cells expressing either E6 or E7 from HPV16 or 31. HFKs or HFKs transduced with either HPV31 E7 (a) or HPV31 E6 (b) were treated with
100 μMDFO for the indicated times, and analyzed byWestern blot for HIF-1α expression. (c) HFK cells or HFKs expressing the indicated HPV16 oncogenes were treated with 100 μM
DFO for the indicated times and analyzed by Western blot for HIF-1α expression.
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McCune et al., 1997; Smith-McCune and Weidner, 1994). From the
early stages of infection to lesion development and eventually
progression to cancer, HPV modulates the cellular response to
hypoxia. Our results indicate that HPV enhances the levels of HIF-1α
through protein stabilization, resulting in the increased expression of
a subset of HIF-1 target genes. This enhanced expression likely plays a
central role in the progression of HPV-induced disease.
Our studies provide insight into how HIF-1α levels are manipu-
lated by HPV proteins. We found that upregulation of HIF-1α by HPV
proteins was not limited to cervical cancers: keratinocytes stably
maintaining HPV genomes, which model cells of early, precancerous
lesions, also upregulated HIF-1α. Furthermore, both high-risk HPV16
and 31 as well as the low risk HPV11 were found to be equally capable
of enhancing HIF-1α levels, indicating that manipulation of the
hypoxic response is important for many papillomavirus types. This
may not be surprising, given that nutrient and oxygen delivery are
required in proliferating lesions regardless of whether they are
induced by high or low risk viruses. Our studies also indicate that
the effects of HPV proteins on HIF-1α levels occur speciﬁcally in
hypoxia, with no detectible effect in normoxia. Since cervical tissues
have characteristics of chronic hypoxia even under normal conditions
(Lee et al., 2007; Mayer et al., 2004; Smith-McCune et al., 1997), HPV-
infected cervical cells in vivo may activate angiogenic factors before
the development of high-grade cancers.
A wide range of cellular factors and pathways have been reported
to affect HIF-1α protein levels (Bardos and Ashcroft, 2005; Brat et al.,
2003). A previous report (Huh et al., 2007) has shown that E7 can
interact with a cullin-2 ubiquitin ligase complex that has been
reported to mediate VHL-dependent HIF-1α degradation (Brat et al.,
2003). Alteration of the activity of this complex by E7 should affect the
level of HIF-1α in normoxia. However, we failed to detect HIF-1α in
normoxia, even in cells expressing E7. This suggests that the normal
VHL-mediated HIF-1α degradation pathway still functions in HPV-
infected cells regardless of any effects E7 may have on other aspectsFig. 6. Effect of HPV11 on HIF-1α induction. HFKs or HFKs containing HPV11 episomes
were treated with 100 μM DFO for the indicated time and analyzed byWestern blotting
for the expression of HIF-1α.the VHL pathway. Furthermore, there was no strong effect of
rapamycin on HIF-1α levels, either with or without treatment with
DFO, suggesting that themTOR pathway (Abraham, 2004) is also not a
major player. The loss of PML has been reported to result in hypoxia-
speciﬁc enhancement of HIF-1α induction (Bernardi et al., 2006), and
PML can be targeted by E7 (Bischof et al., 2005). Loss of p53 has also
been reported to enhance HIF-1α induction in hypoxia (Ravi et al.,
2000). Although E6 and E7 affect the absolute levels of p53 protein in
opposite ways, both oncogenes have been reported to affect the
function of p53 (Munger et al., 2004). Both E6 and E7 were
independently sufﬁcient to alter HIF-1α levels, indicating that
activation of HIF-1α in HPV positive cells cannot be strictly dependent
on p53 protein levels, but whether E6 and E7 alter HIF-1α through
alteration of p53 function remains to be determined.
Several studies have shown that high-risk E6 and E7 can activate
expression or enhance levels of a number of angiogenic factors, but it
was not established that HIF-1α activation was responsible (Tous-
saint-Smith et al., 2004). Transfection of siRNAs against HPV18 E6 was
found to reduce VEGF expression in HeLa cells (Clere et al., 2007). In
addition, conditioned supernatants from HPV16 E6 or E7 expressing
cells were able to induce tube formation and proliferation of
endothelial cells consistent with the activation of angiogenic factors
(Bequet-Romero and Lopez-Ocejo, 2000; Chen et al., 2007; Lopez-
Ocejo et al., 2000; Tang et al., 2007). Using transient transfections of
cervical cancer cells, E6 and E7 were able to increase expression of
genes associated with angiogenesis which are also responsive to HIF-1
(Clere et al., 2007; Lopez-Ocejo et al., 2000; Tang et al., 2007). Finally,
transient transfection of E6 and E7 expression vectors into cervical
cancer cell lines was reported to induce HIF-1α levels under normoxic
conditions but without altering protein stability (Tang et al., 2007). In
contrast, our studies using stable cell lines show that HIF-1α can be
upregulated by E6 and E7 but only in hypoxia and through protein
stabilization. We suggest that the hypoxia-speciﬁc stabilization effect
that we report is more likely to reﬂect conditions in vivo, given that
our cells stably express HPV proteins.
The enhanced levels of HIF-1α in HPV positive cells were found to
activate some downstream genes such as VEGF and CAIX. On the other
hand, upregulation of IL8 and GLUT1 were either not seen or not
enhanced in HPV positive cells. This indicates that HPV proteins have a
mechanism to modulate the spectra of HIF-1 target genes that are
activated upon DFO treatment. Studies from the Roman laboratory
(Toussaint-Smith et al., 2004) have shown that cells expressing HPV
oncogenes can induce the expression of angiogenic genes such as
VEGF even in non-hypoxic conditions. The state of HIF-1α was,
however, not examined and it is possible that there was low level
activation in their cells that was not observed in our assays.
Alternatively, it is possible that HIF-1 independent mechanisms are
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levels of VEGF in normoxia showed low levels of expression in HPV
positive cells in the absence of DFO, consistent with HIF-1 indepen-
dent mechanisms of activation. It is also possible that different culture
methods could be responsible for the effects observed. Consistent
with published studies, we have observed that HIF-1α can be induced
at low levels in normoxia by growth at high conﬂuency (data not
shown, see also (Rempe et al., 2007)) which could lead to activation of
angiogenic genes. Our survey of angiogenesis mediators produced in
HPV positive cells was not as complete as Toussaint-Smith et al., but
we note that there appears to have been a somewhat higher
expression of VEGF in HK31 cells and in some experiments CAIX
(not shown) in the absence of DFO treatment. In any case, more
detailed analysis of HIF-1 downstream mediators will be needed to
understand the role of hypoxia and HIF-1α stabilization in the
angiogenic phenotype in HPV infection.
The ability of HPV to inhibit the expression of IL8 transcripts, as
seen in Fig. 4d, was striking, but is consistent with the results of Huang
et al., who observed that E6 and E7 could inhibit IL8 transcription by
binding to coactivators (Huang and McCance, 2002). Future studies
will further clarify this effect.
Finally, it was possible that the replication or transcription of the
HPV31 genomeswas sensitive to hypoxia, but we found that therewas
no effect of 12 h of DFO treatment on viral copy number, and only a
slight increase in viral transcripts and luciferase activity from early
and late promoter reporters (unpublished). Whether viral replication
and gene expression are impacted bymore chronic hypoxia remains to
be determined. In summary, we have found that several HPV types
cause an enhancement of HIF-1α expression in hypoxia, an effect
mediated by increasing stability of the HIF-1α protein. Furthermore,
this increased HIF-1α expression is reﬂected in increases in some but
not all downstream effectors of the hypoxic response, and is seen
upon the expression of either E6 or E7. These results shed light on the
relationship between HPV infection and hypoxia in the development
of cervical cancer and may help us better understand how to manage
HPV-induced disease.
Materials and methods
Cell culture and creation of cell lines
Keratinocyte-derived cell lines were cultured in E-medium con-
taining mouse epidermal growth factor (5 ng/ml; BD Biosciences)
with mitomycin C (Medac)-treated NIH 3T3 J2 ﬁbroblast feeders as
described previously (Meyers and Laimins, 1994). Prior to harvesting
keratinocytes for analysis, feeders were removed via treatment with
versene. To create cell lines containing HPV31 episomes, cloned viral
DNA was freed from its plasmid vector by digestion with HindIII,
unimolecularly ligated with T4 DNA ligase (New England Biolabs)
overnight at 16 °C, and precipitated with isopropyl alcohol. Human
foreskin keratinocytes (HFKs) were transfected with HPV genomes,
selected with G418, and pooled cell populations were expanded and
analyzed for episomal maintenance as described previously (Wilson
and Laimins, 2005). Creation of retroviral constructs has been
described previously (Halbert et al., 1991; Moody et al., 2007).
Hypoxia was mimicked by treatment with 100 μM deferoxamine
mesylate (DFO, Sigma). Cycloheximide and rapamycin were obtained
from Sigma.
Western blot analysis
Whole cell extracts were prepared using 1× lysis buffer (Cell
Signaling) and concentrations were determined using the Bio-Rad
(Bradford) protein assay. SDS-PAGE and Western blotting were
performed as described previously using 50–100 μg of protein
(Hebner et al., 2006). HIF-1α antbody (BD Biosciences) was used at1:500, and GAPDH (Abcam) 1:20,000. Densitometry was performed
using Scion Image for Windows (Scion Corp.)
RNA analyses
Total RNAwas isolatedusingRNASTAT-60 (Tel-Test) according to the
manufacturer's directions, and Northern analysis was performed on
total RNAs aspreviously described (Wilsonet al., 2005). Total RNAswere
reverse transcribed using the Omniscript RT kit (Qiagen) and subject to
real time PCR analysis using primers speciﬁc for human VEGF (5′-
TCTACCTCCACCATGCCAAGT-3′, and 5′-GATGATTCTGCCCTCCTCCTT-3′),
SYBR green PCR master mix (Applied Biosystems), and an ABI 7900 HT
sequence detection system following the manufacturer's directions.
Ribonuclease protection assays were performed using the RPA III kit
from Ambion as described previously (Bodily and Meyers, 2005). The
probe for Interleukin-8 (IL8) was cloned by PCR into the KpnI/HindIII
sites of pGEM 7Zf(+) using Vent polymerase (New England Biolabs)
using primers 5′-GCCGGTACCATGACTTCCAAGCTGGCCG-3′ and 5′-
GCCAAGCTTCTTTGATAAATTTGGGGTGG-3′. The template (BCMGS neo
IL8) was a gift from Steven Polyak at the University of Washington,
Seattle, WA and was originally constructed by Naofumi Mukaida,
Kanazawa University, Kanazawa, Japan. The internal control for
cyclophilin was purchased from Ambion. The CAIX and GLUT1 cDNAs
were cloned into pcDNA 3.1(−) by RT-PCR using primers 5′-
CGCCTCGAGGCATGGCTCCCCTGTGCCCC-3′ and 5′-CGCGGTACCTC-
CAGCCTCTAGGCTCCAGT-3′ for CAIX, and 5′-CGCCTCGAG CTGCCATG-
GAGCCCAGCAGC-3′ and 5′-CGCGGTACCGGCGACTCACACTTGGGAAT-3′
for GLUT1. A cDNA encoding HIF-1α cloned into pcDNAwas a gift of Eric
Huang (NIH). Northern probe templates were generated from pcDNA-
derived plasmids by PCR using the T7 and SP6 primers, and Northern
analysis was performed using 10–15 μg total RNA as described
previously (Fehrmann et al., 2003).
Luciferase assays
A luciferase reporter consisting of a trimerized 24-mer containing
18 base pairs from the hypoxia response element (HRE) of the
phosphoglycerate kinase promoter, HRE-TK-Luc, was a gift from
Navdeep Chandel, Department of Medicine, Northwestern University,
Chicago, IL. Cells were plated in a six-well dish the day prior to
transfection and cotransfected with 1 μg of a luciferase reporter and
50 ng of the Renilla control vector pRL-TK (Promega) using FuGene
(Roche Diagnostics) according to the manufacturer's instructions.
After overnight incubation, cells were treated with or without DFO for
8 h and then harvested for luciferase assay using the Dual Luciferase
kit (Promega) according to the manufacturer's instructions. Transfec-
tion efﬁciencies were normalized for Renilla luciferase activity. HIF-1
dependent activity was calculated as the ratio of the activity in cells
treated with DFO to that without DFO.
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